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Background: Because of their individual rarity, genetic diseases and other types of rare diseases are under-represented
in healthcare coding systems; this contributes to a lack of ascertainment and recognition of their importance for healthcare
planning and resource allocation, and prevents clinical research from being performed.
Methods: Orphanet was given the task to develop an inventory of rare diseases and a classification system which could
serve as a template to update International terminologies. When the World Health Organization (WHO) launched the
revision process of the International Classification of Diseases (ICD), a Topic Advisory Group for rare diseases was
established, managed by Orphanet and funded by the European Commission.
Results: So far 5,400 rare diseases listed in the Orphanet database have an endorsed representation in the foundation layer
of ICD-11, and are thus provided with a unique identifier in the Beta version of ICD-11, which is 10 times more than in
ICD10. A rare disease linearization is also planned. The current beta version is open for public consultation and comments,
and to be used for field testing. The adoption by the World Health Assembly is planned for 2017.
Conclusions: The overall revision process was carried out with very limited means considering its scope, ambition and
strategic significance, and experienced significant hurdles and setbacks. The lack of funding impacted the level of
professionalism that could be attained. The contrast between the initially declared goals and the currently foreseen final
product is disappointing. In the context of uncertainty around the outcome of the field testing and the potential
willingness of countries to adopt this new version, the European Commission Expert Group on Rare Diseases adopted in
November 2014 a recommendation for health care coding systems to consider using ORPHA codes in addition to ICD10
codes for rare diseases having no specific ICD10 codes. The Orphanet terminology, classifications and mappings with other
terminologies are freely available at www.orphadata.org.
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Because of their individual rarity, genetic diseases and
other types of rare diseases are under-represented in
healthcare coding systems; this contributes to a lack of
ascertainment and recognition of their importance for
healthcare planning and resource allocation, and pre-
vents clinical research from being performed. This re-
sults in a poor understanding of their natural history
and lack of knowledge of their epidemiology.* Correspondence: segolene.ayme@inserm.fr
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unless otherwise stated.There are several thousands of rare diseases, disorders
and conditions, the exact number being impossible to es-
tablish as it depends directly on the definition of not only
what is the threshold for rarity but also on what is the def-
inition of a clinical entity. The threshold for rarity is defined
in some regions of the world in the context of regulations
put in place to boost the development of therapies for rare
diseases through incentives for Industry to invest [1]. It is
based on the concept of prevalence or maximum number
of patients in a region and ranges roughly from 1 in 10,000
to 1 in 1,000 persons. The definition in the European
Union, as established by the Regulation (EC) N°141/2000 of
the European Parliament and of the Council of 16This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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prevalence of no more than 1 in 2′000.
Until recently there was no systematic effort to estab-
lish an inventory of rare disorders, except in the field of
genetic defects where the Online Mendelian Inheritance
in Man (OMIM) had started to document knowledge on
genetic phenotypes as a proxy for genes, then on human
genes when identified, as early as 1966 [3]. The compilation
of an inventory of rare diseases, beyond genetic diseases,
started in a systematic way in 1996, in the context of the
rare disease database and knowledge base, Orphanet, estab-
lished jointly by the French National Institute of Health
and Medical Research (INSERM) and the French Ministry
of Health [4] before becoming a Joint Action between the
member countries of the European Union [5]. Orphanet
not only collected information on rare diseases published
in the scientific literature, but also classified them, from
2007 onwards, with a poly-hierarchy approach, each clinical
entity being assigned an Orpha number. This effort was
supported by the European Commission which not only
co-financed Orphanet from 2001 onwards, but also estab-
lished, in January 2004, a Rare Diseases Task Force with the
mandate to contribute improve the codification of rare dis-
eases, amongst other public health objectives.
This was instrumental in the decision to propose in
2007 that WHO make use of the Orphanet data to up-
date ICD10 and design ICD11. This led to the establish-
ment, in 2009, of a WHO Topic Advisory Group for
Rare Diseases whose efforts and achievements are pre-
sented in this article.State of play of rare diseases coding in ICD10
An assessment of the number of rare clinical entities
having a specific code in ICD10 can be derived from the
effort carried out by Orphanet to cross-reference Orpha
codes with ICD10 codes, starting from the Orphanet list
of rare clinical entities defined as a clinically unique, dis-
tinct entity, whatever the number and nature of the
causes, and following the European definition for rarity,
i.e. a prevalence equal of no more than 1 in 2,000 in the
general population of Europe. The cross-referencing is
based on the 2010 online version of the ICD-10, but
takes into account the official WHO updates endorsed
in 2011 and 2012. In January 2015, among the over
6,954 clinical entities listed by Orphanet, 355 of them
only have a unique specific code in ICD 10 and 162 can
be specifically mapped to a set of ICD10 codes.
In fact the situation is complex as one ICD code
sometimes corresponds to one Orpha code, but also one
ICD code can correspond to a group of rare entities or
to a group of both rare and non-rare entities. To in-
crease rare disease representation in ICD-11, the object-
ive is to expand the number of specific codes.Orpha codes have also been mapped with UMLS ter-
minologies [6]. In 2013 (UMLS-AB 2013 version) 32%,
23% and 14% of the Orphanet rare clinical entities had
equivalent counterparts in SNOMED CT, MeSH, and
MedDRA, respectively. These results demonstrate the
necessity to expand the current coding systems so as to
fairly represent entities which have a very significant im-
pact on the healthcare systems and that are targets for
innovation.The ICD revision process up-to-now
The World Health Organization established various Topic
Advisory Groups (TAGs) to serve as planning and co-
ordinating advisory bodies in the update and revision
process for specific areas (Figure 1). They were given
the task of inviting working groups or individual experts
to review their proposals. Each TAG is run by a chair
and a managing editor [7]. A Revision Steering Group
(RSG) including TAG chairs, representatives of the
WHO-FIC (World Health Organization Family of Inter-
national Classifications) Network, other invited termin-
ologies, classification and public health experts, and
relevant WHO officers were charged with overseeing
the overall revision process through monthly teleconfer-
ences [8].
The revision process started in 2007. The RSG met for
the first time in April 2007 to set out plans and define
goals for the upcoming ICD-11. During the next meet-
ings, the Health Informatics and Modelling (HIM) TAG
was in charge of drafting the conceptual framework of
entities and of developing Internet-based collaborative
editing tools. A first project based on a wiki (Lexwiki)
was rejected and replaced by a Protégé-based web-
platform developed by a Stanford University team: the
ICD Collaborative Authoring Tool (iCAT).
The official launch of the revision took place in September
2009 during a general meeting of TAG chairs and managing
editors at the WHO headquarters in Geneva (‘i-Camp”). The
revision proceeded in two phases. From September
2009 to May 2012, the TAGs worked to produce a first
version of ICD-11 called the alpha-draft, using the
iCAT. A public browser was opened in May 2011 to
allow the public to view and then (from July 2011 on) to
comment the alpha draft. From May 2012 onwards, the
revision transitioned towards developing the beta-draft,
which intends to be a relatively stable, reviewed draft fit
for field testing use. The beta-draft was frozen in August
2014 to enable field trials to begin. Further comments
are still collected on the public browser, and dispatched
by the WHO to the relevant TAGs; corrections are from
then now on implemented as a whole in periodic up-
dates of the beta-draft. The first of those updates was
published on early October 2014.
Figure 1 ICD Revision organizational structure.
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The current ICD-10 classification is mono-hierarchical:
meaning that every entity can figure only at one point in
the classification. The historical rationale for this choice
was to avoid double counting, since the ICD is primarily
used as a statistical tool. This is a problem however for
numerous diseases that can be associated with more
than one body system, as chapters are broadly organised
along them. In such cases, one system must then be
given priority, and “exclusion notes” are put in the other
relevant chapters to redirect users to the correct code.
The levels of detail in ICD-10 are limited to four: chapter
(e.g. IV Endocrine, nutritional and metabolic diseases),
block of codes (e.g. E70-E90 Metabolic disorders), three-
character codes (e.g. E70 Disorders of aromatic amino-acid
metabolism) and four-character codes (e.g. E70.0 Classical
phenylketonuria). Additional details can be added only in
clinical modifications used at the national level.
In the ICD-11, the classification is poly-hierarchical, and
every entity is assigned a unique identifier. Diseases can
figure in all places relevant for them in the tree structure;
for instance, the several endocrine diseases associated with
developmental anomalies will figure both in the endocrine
and developmental anomalies chapters. This comprehen-
sive tree-structure is called the foundation. It will be fully
accessible in the electronic version of ICD11.
However, it is still necessary to keep the possibility of
using a mono-hierarchical system: for space reasons in
paper versions; to bundle data at specific levels for ana-
lysis; and most of all for statistics, to avoid double count-
ing. Therefore, the ICD-11 will also feature linearizations,
i.e. simplified versions arranged from a subset of the foun-
dation to allow for a mono-hierarchical view of ICD-11 in
which all selected items are mutually exclusive andjointly exhaustive for statistical purposes. Several lineari-
zations are planned to accommodate various use cases: a
joint linearization for mortality and morbidity statistics;
two primary care linearizations, for low and high resource
settings respectively; and several specialty linearizations,
notably for dermatology, ophthalmology and rare diseases.
ICD-11 will feature up to seven levels of detail within
every chapter. However, only the first three will be used
in international comparisons; the additional four levels
of detail will remain available for specific uses. It is thus
important to ensure that important entities are visible in
the first three levels.
In principle, every ICD-11 entity should be defined by el-
ements of a content model [9], including a title, classifica-
tion properties, a set of synonyms and inclusion terms,
textual definitions and various associated properties. These
datasets were designed to allow an ontological approach to
ICD-11 entities [10]. The full set of parameters is described
in Table 1.
Methods
Involvement of the rare diseases TAG
The Rare Diseases TAG was established in April 2007 to
ensure that rare diseases would now be traceable in
mortality and morbidity information systems (Table 2) .
The production of basic information on which to build
the classification of rare diseases in ICD-11 was assigned
to Orphanet. It contributed to the whole ICD revision
process, considering that rare diseases involve all areas of
medicine. Orphanet collects series of rare diseases classifi-
cations mainly based on scientific grounds (etiology and
mechanism). To complement these classifications, a clin-
ical in-house classification is developed to meet the needs
of the clinicians. All the classifications, regularly updated
Table 1 List of field of the content model of ICD11




5. Body system/structure description .
6. Temporal properties




11. Specific condition properties
12. Treatment properties
13. Diagnostic criteria
Not all fields are mandatory: the only required parameters that those relevant
to the description of the entity. The main focus has been set on filling the first
seven parameters.
World Health Organization. WHO ICD Revision Information Note n°4: ICD-11
Content Model. Online on the WHO
website: http://www.who.int/classifications/icd/revision/
Information_Note_4_Content_Model_v.1.4Approved.pdf?ua=1.
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Orphanet website and have served as a basis to build the
ICD-11 proposals by the Rare Diseases TAG.
For chapters where rare diseases feature prominently,
or were dealt with early in the revision process, the Rare
Diseases TAG proposed a whole revision of the structure
together with the addition of rare diseases. These are the
chapters for the blood and immune systems (ICD-10
chapter III), endocrine system, nutritional and metabol-
ism (ch. IV), nervous system (ch. VI), respiratory system
(ch. X), and developmental anomalies (ch. XVII).
For the other chapters, the new structure revision has
been set up by the specific TAG for the body system and
rare diseases were added into it by the Rare Diseases TAG.
These are the chapters for infectious and parasitic diseases
(ch. I), neoplasms (ch. II), eye (ICD-10 ch. VII), ear (ICD-
10 ch. VIII), circulatory system (ch. IX), digestive system
(ch. XI), skin (ch. XII), musculoskeletal and connectiveTable 2 WHO Rare Diseases Topic Advisory Group
membership
Chair: Pr. Ségolène Aymé
Managing editors: Dr. Ana Rath and Bertrand Bellet
Representatives for specific areas:
• Dr. Eduardo Castilla (Brazil)
• Pr. Evgeny Ginter (Russia)
• Dr. Stephen Groft (United States)
• Pr. Julie McGaughran (Australia)
• Ms. Kerry Innes (Australia)
• Dr. Judith Allanson, afterwards replaced by Ms. Marion Williams (Canada)tissue (ch. XIII), genitourinary system (ch. XIV), preg-
nancy, childbirth and the puerperium (ch. XV), perinatal
conditions (ch. XVI).
No proposal was made in the chapter on mental and be-
havioral disorders (ch. V). The reason is that the mental
and behavioral disorders chapter is set up to allow the
coding of levels of disabilities independently from their
cause. Therefore it was not possible to establish new levels
of coding to include rare diseases impacting on mental
status and behavior, but conditions with disorders of intel-
lectual developmental as a relevant clinical feature were
listed in a dedicated grouping in the chapter for develop-
mental anomalies. The inclusion of a new chapter for
multi-systemic diseases was considered for a time and ad-
vocated for by the Rare Diseases TAG. Nevertheless, the
WHO decided against its creation and struck out the in-
work draft chapter in the iCAT on December 2011. The
diseases that it would have contained were later redistrib-
uted into chapters for the individual body systems.
The WHO introduced during the writing of the alpha-
draft a division of labor between TAGs when their areas
of interest overlapped. The Rare Disease TAGs fre-
quently experienced it, since rare diseases are found in
every area of medicine. In such instances, the WHO
assigned the primary responsibility for a chapter or sec-
tion structure to a “primary TAG”, while other interested
TAGs remained free to add and edit information. The
Rare Diseases TAG was the primary TAG only for the
section on developmental anomalies (ch. XVII).
Revision procedures followed by the rare diseases TAG
For chapters where the Rare Diseases TAG proposed a full
structural revision, the first stage was a systematic com-
parison between the extant ICD-10 and the Orphanet
classifications of rare diseases. These classifications are
produced and updated for the Orphanet database from a
synthesis of medical and scientific publications, workshops
with expert groups, and direct validation by specialists for
restricted groups of disorders. The workflow is described
in Figure 2.
General lines were defined. The chapters were organized
primarily on a clinical basis, in line with the mortality and
morbidity linearization. Etiology was considered after-
wards for further detail. Genetic diseases were classified
according to their clinical manifestations. However, they
may be identified as genetic in the content model (from
the Causal properties section), thus enabling to retrieve
them separately. Rare diseases affecting several body sys-
tems were included in every relevant chapter, in accord-
ance with the poly-hierarchical line of ICD11; but a main
localization was suggested, to prepare for morbidity linear-
izations, according to the most severe involvement and/or
the medical speciality most likely to be relied on for the
management of the disease. In some cases, the choice is
Figure 2 Workflow followed by the Rare Diseases TAG for the preparation of the ICD11 Alpha-draft.
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sion. Tumors were systematically doubly classified in the
chapter for neoplasms and in the chapter(s) dedicated to
the involved body system(s). Morphologically-defined tu-
mors, currently coded with ICD-O, were included in the
draft. Constitutional and acquired disorders were regularly
distinguished in the hierarchical structure of revised chap-
ters. Categories inherited from the ICD-10 were systemat-
ically examined, and preserved as far as possible for the
sake of historical continuity. However, the latter require-
ment was only clearly expressed at the beginning of the
beta-draft phase; therefore, several drafts already corrected
by experts had to be subsequently amended.
From this structural comparison, a draft for a new
structure was written as a starting point to submit to
working groups and experts. The drafts were sent by
mail as PDF files, containing the rationale and general
principles for the ICD revision and the revised structure,
presented with synonyms and mappings with Orpha
numbers. Working groups and experts for Europe were
invited by the chair of the Rare Disease TAG. The other
TAG members were responsible for disseminating the
draft and invitation to contribute in their respectivegeographic areas: Brazil, Russia, United States, Canada,
Australia, and to forward the collected feedback for ana-
lysis by the managing editor and assistant. From this
feedback, a second, corrected draft was produced and
sent for validation to the same experts.
For the revision of the chapter for developmental
anomalies, for which the Rare Diseases TAG had pri-
mary responsibility, experts met in a conference held on
December 2011 in Luxembourg to address the chapter’s
structure after having been previously submitted a first
draft and sent their preliminary feedback.
The implementation of the revised chapters in the
iCAT has been variable across time. The first chapters
were revised before the iCAT was functioning. Later,
chapters were entered into the iCAT when the draft had
been reviewed twice and validated by experts. Finally,
chapters were entered into the ICAT directly at the stage
of the first draft in order to allow other TAGs to com-
ment them as well, and corrections submitted by experts
made later as they were received.
Once the revision transitioned to the beta-phase, the
Rare Disease TAG’s work shifted to ensuring that the
rare diseases it had introduced into the ICD-11 structure
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commodations with the requirements of other TAGs re-
garding their dedicated chapters, and to mapping iCAT
and Orphanet identifiers to enable exchange of data be-
tween the two systems, notably in the prospect of popu-
lating of the ICD-11 content model with Orphanet data.
Several hundreds of definitions for rare diseases have
already been imported into the iCAT in that way. This
mapping has to be regularly updated as the ICD-11 con-
tent is still evolving, notably by the reduction of dupli-
cates and the redefinition of certain entities.Results
Current situation of rare diseases in ICD 11
On 1 October 2014, 5,400 rare diseases listed in the
Orphanet database have an endorsed representation in
the foundation layer of the ICD-11, and are thus pro-
vided with a unique identifier in ICD-11, which is 10
times more than in ICD10. A mapping of those identi-
fiers with ORPHA numbers has been established to
allow data exchange and to ensure compatibility between
the two information systems; it will need to be regularly
updated as new frozen releases of the ICD-11 beta ver-
sion are issued.
The content model is far from complete for most
ICD-11 entities and in all likelihood will never be com-
pleted. The amount of data to be gathered is simply too
great for the limited means available to the editors, both
in terms of time and funding. Besides, keeping such a
large repository of data up-to-date is bound to become
quickly overwhelming, especially regarding genetic data
which are rapidly evolving. The only realistic way to
achieve the initial purpose of annotating ICD-11 entities
with the planned set of properties at a professional level
of quality would be for the WHO to establish long-time
partnerships with stable institutions dedicated to gather-
ing and managing the relevant biomedical data.
In the meantime, the focus on filling the whole of the
content model has been scaled down: emphasis is now
chiefly put on writing definitions for every disease in
ICD-11. At least, this will allow the codes to be used
without ambiguity. Around 4,000 rare diseases repre-
sented in ICAT have an associated definition so far:
2,600 were expressly created by the Rare Diseases TAG,
the remaining 1,400 were imported or created by other
groups and need yet to be reviewed by the Rare Diseases
TAG. 1,400 definitions remain to be written.
The current state of the ICD-11 beta version is open to
the public for consultation and comment on an online
platform: http://apps.who.int/classifications/icd11/browse/
f/en#/. Everybody is entitled to create an account with a
profile and to post comments, which are filtered by the
WHO and dispatched among the relevant TAGs. TheTAGs advise on what is to be done and the corresponding
corrections are then carried out by the WHO.
The beta version is now frozen, so that it may be stable
enough to be used for practical tests in the field. Correc-
tions are nonetheless still possible, but are implemented
globally as packages: the beta version now evolves through
successive releases rather than being in a state of continu-
ous flux. The last frozen releases of the beta version oc-
curred on 14 August 2014 and 1 October 2014.
The work of many TAGs, including the rare disease
TAG, has been largely focused till now on elaborating
the foundation layer. However, the importance of the
linearizations is now clearly emerging. They will be the
tools used in actual practice, each being specifically fit-
ted to a specific use case, while retaining a mutual com-
patibility by their being derived from the common
foundation layer. In some instance they can be regarded
as a “patch”, allowing to work within a framework ex-
pressly tailored for a specific purpose, even when dir-
ectly using the structure from the foundation layer
would be inappropriate or too unwieldy. The most gen-
erally used linearization will doubtlessly be the Joint
Mortality and Morbidity linearization, designed to estab-
lish international epidemiological statistics, according to
the basic purpose of the ICD since its inception; but is not
intended at all to be the only one. Our position is that lin-
earizations should be developed for every specific use case
requiring cross-comparison of institutional data from vari-
ous origins. Specific interest groups should involve them-
selves in creating and publishing their linearizations, so
that they may be clearly and reliably established, fixed and
made known.
The Rare Disease TAG obtained the agreement of
WHO for the creation of a linearization for rare diseases.
It still remains to be practically developed. Other medical
fields that are already planned to have their own specialty
linearization are mental health, dermatology, musculoskel-
etal disease, neurology, paediatrics, occupational health
and ophthalmology. The list is not limitative: other groups
expressed their interest in having a specific tool, notably
for allergology [11]. A linearization for medical genetics
will certainly be required, the creation of which could be
supported by the Rare Diseases TAG
Discussion
The ICD 10th Edition was produced between 1982 and
1989 by annual revision conferences of a limited number
of experts, and it was adopted in 1990 by the World
Health Assembly. It was foreseen that 10-yearly (decen-
nial) editions would continue as the method of revision
with interim annual updates in between. When the 11th
revision was due in 2000, a moratorium was suggested
by the WHO Executive Board for the Secretariat to
come up with a modern revision strategy in consultation
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was the insufficient level of ICD-10 adoption by Member
States: ICD was then used by only 96 Member States
out of 191. The moratorium suggested better informatics
support towards implementation. In the following years,
the WHO addressed the implementation issues within the
WHO Family of International Classifications (WHO FIC)
Network and then formulated a revision strategy between
2003 and 2007. An International Revision Process Plan
was developed to revise the classification content in line
with advances in health sciences and to add the desired
functionality using modern health informatics standards.
The objective was to gather input from all stakeholders in
an open and documented way. The revision process was
initiated by a letter from the Director General of WHO to
all Member States in April 2007.
The strategy adopted by WHO was extremely ambitious
and difficult to implement. The advance of knowledge
since the 1980s (when the basic structure of ICD-10 was
elaborated) makes the need for a general overhaul quite
obvious. It is simultaneously necessary to manage the
transition from paper to electronic records and to make
use of the wide array of new technical possibilities opened
by the development of information technology over the
last two decades. Hence the project of turning the old
ICD-10, primarily thought and used as a reference tool for
statistics, into an ICD-11, intended as a versatile reference
tool for any setting requiring the use of an interoperable
classification of diseases, with features reminiscent (and
allowing the derivative development) of an encyclopedia
and ontology. Unfortunately, the revision proceeded ra-
ther erratically, with very limited means considering its
scope, ambition and strategic significance, and experi-
enced significant hurdles and setbacks. The lack of fund-
ing impacted the level of professionalism that could be
attained. The contrast between the initially declared goals
and the currently foreseen final product is disappointing.Organizational issues
The collaboration between TAGs was left to personal
initiatives only, as the TAGs were not given clear in-
structions on how they should actually work together.
The Rare Disease TAG was especially well-placed to ex-
perience this issue, because its scope of intervention in-
volved nearly every chapters of the ICD and naturally
led it to interact with many of the other TAGs. In prac-
tice, the quality of those relationships was extremely
variable: a few were efficient collaborations, some were
more difficult but ultimately fruitful and resulted in
agreement, but there were also points of utter diver-
gence. The selected model of distributed terminology
development [12] was more an experiment than a real
organizational choice.TAGs were constituted progressively during the revi-
sion process, without a formal process defining in ad-
vance their final number and exact scope of activities:
the division of responsibilities between “primary” and
“secondary” TAGs (see above) occurred only quite late
during writing the alpha-draft. Since the TAGs started
working at various periods, their level of understanding
depended on the number of RSG meetings they could
attend and their ability to explore the collaborative in-
struments. The TAGs that started working later on quite
naturally ignored most of the basic rules agreed on orally
but never explicitly written down in detail in a guidance
document. Notably the full poly-hierarchy of ICD11,
which allows all other TAGs create new hierarchies of dis-
eases assigned to one specific ICD-10 chapter, was not
understood by many TAGs. The absence of a restriction
on levels of detail was not understood either. Several
times, very rare but well-recorded diseases we had added
into the new structure were discarded by the TAG for the
relevant medical specialty as too rare to be of interest, or
better represented as inclusion terms of bundled categor-
ies. This was not acceptable to us and caused many areas
of friction. The necessity of unambiguous names once
read out of context was not respected by most TAGs.
From our experience, the lack of agreement on and ap-
propriation of the basic revision concepts and principles by
the TAGs has been the source of many misunderstandings
between TAGs. We opine that more attention should have
been devoted to dealing collectively with such issues from
the very start of the revision. Not enough time was spent
on educating the medical experts involved in the TAGs on
the requirements of an effective information system. In-
stead, the initial emphasis was rather put on educating
TAG members on using collaborative tools. While there is
of course no question that this was necessary, we argue
that this was premature before the lineaments of this col-
laboration had been effectively settled. The resulting dis-
agreements had to be solved later by time-consuming and
sometimes difficult exchanges of mails, face-to-face meet-
ings and teleconferences.
Many formal rules emerged during the revision
process and were formalized only several years after the
revision had begun. Consequently, the work carried out
on many entities had to be repeated later to adapt the
data to the finally decided format. In view of the limited
means allotted to the revision, this produced an un-
necessarily heavy workload as tasks had to be done and
redone again and again, hence many delays, frustration
and sometimes even anger with the whole process
(resulting for instance in resignation). It is impossible
here not to regret the waste of time that would have
been saved by normalization from the start.
A few examples of this late formulation of rules are now
given. Information notes formalizing various aspects, were
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after the revision process had been launched, and four
years after the preliminary discussions in 2007 [13]. Rules
for the naming of diseases were not clear for many TAGs,
despite the existence of a WHO style guide. In particular,
many names were initially created that made sense only in
the hierarchical framework the entity was included in, but
which would have made little sense in an alphabetical list
like the ICD-11 index. A template on how short defini-
tions should be written has formalized by a dedicated
WHO team in 2014 only [14].
On the whole, there appears in many TAGs to have
been an understandable focus on medical issues but at the
expense of those related to organizing knowledge into an
information system. It shows that the background in infor-
mation science of the revision organizers was unfortu-
nately not transmitted efficiently enough to the experts
participating into the TAGs. Much of their time probably
went into appropriating the tools put at their disposal,
when they actually did, since we are aware that a large
amount of the proposals were finally implemented by
WHO officials. Face-to-face meetings between each TAG
and WHO officials proved to be absolutely necessary be-
fore the beta version could be reasonably put on line.
Alternatively, we think that fully acknowledging this div-
ision of the tasks between medical experts and informa-
tion scientists would have been more efficient. Time and
money could have been saved by gathering information
from medical literature and taking advantage of the clin-
ical modifications of ICD-10 used in various countries.
Some elements of them may have been used during the
revision, but no general analysis was ever presented. The
TAGs missed here an opportunity to obtain a view of the
existing needs of practicing coders on the field, to evaluate
their consistency across countries and compare this feed-
back with the revision directions required by the advance
of knowledge. From those data, a preliminary draft could
have been produced by information professionals accord-
ing to the general principles of ICD-11, as planned by the
RSG. Then this draft would have been submitted to ex-
perts for discussion, and conferences held to establish a
consensus. Finally information professionals would then
have implemented the decided structure in the iCAT and
submitted the result to the experts for validation.
The Rare Diseases TAG used this organization quite
successfully. We also experienced several times the much
greater added value of direct face-to-face discussion com-
pared with mail or even phone calls, and wish to especially
thank all experts that devoted some of their time to us in
order to directly discuss the ICD-11 structure together.
Conceptual issues
The revision process was supposed to produce a coher-
ent classification, based on the current state of science,and adapted to the users’ needs. Unfortunately, the dis-
cussion on the structure happened only at the level of
the Health Informatics and Modeling (HIM) TAG, at the
conceptual level, and never between all the Revision
Steering Group (RSG) members. None of the RSG meet-
ings had a dedicated session for debating the basic prin-
ciples guiding the revision of the structure. The result is
that the current ICD-11 structure is at least as inconsist-
ent as in ICD-10.
From the start of the revision, especially during the pre-
liminary discussions from 2007 to 2009, the HIM TAG
and RSG appear to have been much impressed by the so-
cial networking model on a large scale information project
provided by Wikipedia, the free online encyclopedia that
anyone can edit. It is definitely a successful model of col-
laborative work, with more than 4 600 000 articles in the
English version to date, though at every possible level of
advancement and quality. On the other hand, producing a
generic all-public encyclopedia and a consistent reference
tool for classification are quite different endeavors: while
the former can thrive in a decentralized setting, as topics
are highly diverse and consistency not necessarily an issue
(with the possibility of cross references by internal links),
the latter requires a much more thoroughly formalized
framework. The bottom-to-top approach upheld by the
RSG, especially in the early phases of the revision, might
have been effective to produce a worldwide encyclopedia
of diseases; but to produce a consistent classification, build
a reference consensus and enable continuity with previous
versions of ICD, a complementary top-to-bottom manage-
ment was inescapable from the start. Nonetheless, the
RSG left the TAGs very free (too free) to organize them-
selves and define the main lines of the structures they
were building. An illustration of the result of this lack of
direction is the notably different approaches adopted by
the various TAGs. While such differing approaches may
be commendable when corresponding medical specialties
are considered in isolation, the global result appears to
lack clearly defined classificatory principles. This makes it
more difficult than needed to understand and may be a
hurdle in the future for appropriation by coders. For in-
stance, the chapter on diseases of the digestive system is
mostly divided along anatomical lines (Table 3), when the
chapter for neurology follows a more etiological approach
[15] (Table 4). In the chapter for hematology, it was not
possible to reach a consensus, so two different views coex-
ist: one by classically described clinical groups (anemias,
polycythemias, hemorrhagic diseases, thrombotic diseases
etc.), corresponding to the Rare Diseases TAG draft, one
based on etiology (iron deficiency, vitamin B12 deficiency,
other nutritional and metabolic anemias, hemolytic ane-
mias, etc.), following the requirements of the Hematology
Working Group of the Internal Medicine TAG. Most of
the entities are shared, but the structures are quite
Table 3 Structure of the classification of diseases of the
digestive system in the Beta version of ICD11
▾ Diseases of the digestive system
► Digestive system disorders of fetus and newborn
► Symtoms, signs and clinical findings involving the
digestive system and abdomen
► Disease and disorders of orofacial complex
► Diseases of oesophagus
► Disease of stomach
► Disease of duodenum
▸ Diverticular disease
► Diseases of small intestine
► Diseases of appendix
► Diseases of large intestine
► Diseases of anal canal
► Diseases of liver
► Diseases of gallbladder and biliary tract
► Diseases of pancreas
► Diseases of peritoneum
► Hernia
► Functional gastrointestinal disorders
► Other diseases of the digestive system
► Symptomsm, findings and clinical forms of the digestive system
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depending on which one is chosen for aggregating data.
According to the ICD revision procedures, a common clas-
sification should have been elaborated in the foundation
layer of ICD-11; specific views are supposed to be repre-
sented at the linearization level, adapted for different use
cases. As a final example, the chapter for circulatory dis-
eases uses several approaches simultaneously, which makes
it quite difficult to approach as a tree-structure (Table 5).
Multi-classified entities are often heterogeneously
treated because of lack of rules on how to manage
multi-classification of entities vs. classifying a disease
and its particular manifestations. It was stated early that
the dagger-and-asterisk system used in ICD-10 to repre-
sent primary and secondary involvement would be dis-
continued. Unfortunately, for a long time it was not
made clear how it was to be replaced. Therefore, TAGs
faced with the need to represent secondary involve-
ments, or specific manifestations of a particular diseases,
tried a variety of creative solutions resulting in great het-
erogeneity across chapters. The typical case was an in-
fectious or multi-systemic disease created several times
for every of its various manifestations, without them be-
ing associated anywhere under a common heading
representing the disease as a whole, or the heading
might have been created without including or ranging
over subtypes for the various manifestations. Thisproblem was acute for a long time but is now solved
(largely by WHO officials) by establishing the correct
parentings. Nevertheless, there are still lingering prob-
lems; for instance, in the digestive chapters, ulcers
caused by Crohn disease or sarcoidosis have no formal
link with Crohn disease or sarcoidosis.
Technical issues
The iCAT tool had some limitations, although secondary
compared to the organizational and conceptual issues
described above. It must be made clear that those limita-
tions are due to the lack of proper funding to sustain
this ambitious process, after the main application ini-
tially developed had been turned down. The iCAT tool
has been developed afterwards on a voluntary basis by a
very small, but fortunately very skilled, reactive and
committed team.
While effective and user-friendly for documenting dis-
eases and managing hierarchies, the iCAT has not been
designed to accommodate differences of views among
editors in a multi-authored process. The choice was
made to allow any editor to edit any entity; as a result,
before editing rights were gradually restricted during the
beta-draft phase, the final stage reflected the decision of
the last editor, and could always be challenged again,
resulting in great instability. The only way to point out
differences was to leave editorial notes, as the tool allows
every data to be annotated in free text. While this fea-
ture is clearly helpful for documenting the reason for
changes and citing source, it proved unusable in practice
to hold sustained discussions between editors, which
have been therefore conducted mostly by private e-mail,
and are therefore not available on the platform for con-
sultation and citation.
The problem has been addressed in the ICD-11 beta
browser, on which the general public is invited to consult
and comment the forthcoming ICD-11: here a more cen-
tralized system has been set out, where comments are fil-
tered by the WHO and dispatched to the relevant TAGs.
The inability of the iCAT to manage editorial rights
and duties, coupled with the absence of clear rules,
ended up creating a stressful situation where thousands
of hours of work could be erased by another group
modifying the iCAT content without any dialogue, with-
out possibility to restore a previous version. This was
counterproductive and disrespectful. It was a waste of
resources ending up with a chaotic final product.
At the beginning of the revision, the platform’s in-
ternal search engine was quite inefficient and worked
only on exact matches between character strings in en-
tity titles. It did not effectively allow for a user to check
whether an entity intended for creation by a TAG had
not already been added before by another one. Since
there are naturally many overlaps between the fields of
Table 4 Structure of the classification of diseases of the
nervous system in the Beta version of ICD11
▾ Diseases of the nervous system
► Infections of the nervous system
► Movement disorders
► Neurological disorders with neurocognitive impairment as a major
feature
► Multiple sclerosis and other white matter disorders
► Epilepsy and seizures
► Headache disorders
► Cerebrovascular diseases
► Spinal cord disorders excluding trauma
► Motor neuron diseases and related disorders
► Disorders of nerve root, plexus and peripheral nerves
► Diseases of neuromuscular junction and muscle
► Cerebral palsy
► Structural development anomalies of the nervous system
► Syndromes with central anomalies of the nervous system
► Disorders of cerebrospinal fluid pressure and flow
► Injuries of the nervous system
► Paraneoplastic and autoimmune disorders of the nervous system
► Disorders of autonomic nervous system
► Prion diseases
► Disorders of consciousness
► Other disorders of the nervous system
► Functional clinical forms of the nervous system
► Symptoms, sign and clinical findings involving the nervous system
► Infections due to prions
► Symptoms, findings and clinical forms of the nervous system
Table 5 Structure of the classification of diseases of the
circulatory system in the Beta version of ICD11
▾ Diseases of the circulatory system
► Neoplasms of the circulatory system
► Cerebrovascular diseases
► Symptoms and signs involving the circulatory system
► Hypertensive diseases
► Ischaemic heart diseases
► Diseases of coronary artery
► Pulmonary heart disease and diseases of pulmonary circulation
► Pericarditis
► Acute and subacute endocarditis
► Heart valve disease
► Rheumatic heart disease
► Diseases of the myocardium
► Cardiac arrhythmia
▸ Congenital anomaly of heart and great vessels and related acquired
abnormalities
► Structural developmental anomalies of the pericardium
► Structural development anomalies of the peripheral vascular system
► Heart failure
▸ Certain specified forms of heart disease
► Complications and ill-defined descriptions of heart disease
► Diseases of arteries and arterioles
► Diseases of veins
► Functional vascular disorders
► Disorders of lymphatic vessels and lymph nodes
► Certain specified disorders of the circulatory system
► Hypotensions
► Postprocedural disorders of circulatory system
► Infections of the circulatory system
► Symptoms, findings and clinical forms of the circulatory system
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the production of a massive amount of duplicate entries,
that had later to be detected (partly with the help of
automatic scripts) and solved one by one by hand. This
pruning was near to reaching completion in September
2014, as far as detected duplicates are concerned. It
must be emphasized however that this was a frustrating
and time-consuming task, which would have been at
least partly avoided by delaying work on the iCAT before
the search engine had been fixed to provide a reasonably
effective safeguard against the creation of so many dupli-
cates. There also remains the possibility of duplicates at
a conceptual, not lexical level, i.e. the coexistence of en-
tities that have a very similar scope but are named so
differently that it is impossible to detect the problem by
purely formal means. There is no other way for now
other than relying on the expertise of the TAGs to deal
with this issue.Conclusions
Currently, only a small fraction of rare diseases have
codes in international nomenclatures, especially in
ICD10, making it impossible to trace patients with rare
diseases in health information systems on a national and
international level. Having codes for each and every rare
disease would help obtain a better knowledge of health-
care pathways and of their impact on specialized health
care services and on budgets. The existence of specific
codes for rare diseases are key to evaluate the perform-
ance of the European reference networks of centres of
expertise for rare diseases which are about to be
implemented.
It would also provide data for clinical research which
is critically needed in this field, and would allow genom-
ics activity, which is growing fast in developed countries,
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next-generation phenotyping [16]. The provided classifi-
cations need to offer a wide range of granularity level in
order to code rare disease patients in different care set-
tings, from primary care to centres of expertise for rare
diseases, from clinical diagnosis up to genetic diagnosis
The revision of the International Classification of Dis-
eases, which is the main instrument at world level, to
code health events and draw statistics for International
comparisons, is in its final stage. The current beta ver-
sion is open for public consultation and comments, and
for field testing use. The adoption by the World Health
Assembly is planned for 2017. In the context of uncer-
tainty around the outcome of the field testing and the
potential willingness of countries to adopt this new ver-
sion, the European Commission Expert Group on Rare
Diseases adopted in November 2014 a recommendation
for national health care coding systems to consider using
ORPHA codes in addition to ICD10 codes when a rare
disease has no specific ICD10 code [17]. As Orpha codes
will be linked with ICD11 the switch from ICD10 to
ICD11 will be made easier if decided.
It is not fair to the large community of patients with
rare diseases, not to make their case visible in health in-
formation systems, and a solution should be adopted at
least until the ICD11 is fully implemented in countries.
An intermediate solution for the codification of rare dis-
eases could be to add the ORPHA code to the current
coding systems. The Orphanet terminology and classifi-
cations, and their mapping with other terminologies are
freely available under Creative Commons Attribution-
NoDerivs Licence, in computable user-friendly formats
at www.orphadata.org (xml format or through the
Orphanet Rare Diseases Ontology (ORDO) in OWL and
boo formats). Two European countries, France and
Germany, have already decided to adopt ORPHA codes
as a complement to ICD10 and are in the pilot phase of
implementation. Fourteen other European countries are
considering the use of Orphacodes at national level and
in some instances this is already a planned measure of
their national plans/strategies for rare diseases [18].
ORPHA codes are already in use in some Italian regions
covering half of the Italian population and the exploit-
ation of the generated data demonstrate how useful this
approach can be [19].Availability of supporting data
All classifications compiled by the Orphanet team are
freely accessible at www.orphadata.org.
The beta version of ICD11 is accessible at http://apps.
who.int/classifications/icd11/browse/f/en#/
Some committees and learned societies systematically
received proposals to review:– For the EC Rare Diseases Task Force/ European
Union Committee of Experts on Rare Diseases: Mr.
Andrew Devereau (United Kingdom), Dr. Shane
McKee (UK), Dr. Domenica Taruscio (Italy), Mrs.
Annet Sollie (Netherlands), Mr. Oscar Zurriaga
(Spain)
– For the European Medicines Agency’s Committee
for Orphan Medicinal Products: Dr. Jordi
Llinares-Garcia
– For the Paediatric Chairs of Canada : Dr. Robert
Armstrong, Dr. Jim Kellner, Dr. William Bingham,
Dr. Cheryl Rockman-Greenberg, Dr. Guido Filler,
Dr. Lennox Huang, Dr. Denis Daneman, Dr. Sarah
Jones, Dr. Joseph Reisman, Dr. Bruno Piedboeuf, Dr.
Harvey Guyda, Dr. Marc Girard, Dr. Herve Walti,
Dr. Jonathan Kronick, Dr. Cathy Vardy, Dr. Aneal
Khan, Dr. Bruno Maranda, Dr. Jonathan Kronick,
Dr. Jane Gillis
– For the National Center for Research Resources
(United States): Dr. Barbara Alving
– For the National Library of Medicine (United
States): Dr. Donald Lindbergh, Ms. Betsy
Humphreys
– For the National Institute of Health Clinical Center
Hospital (United States): Dr. John Gallin
Individual experts were contacted according to their
well-identified expertise or their role as coordinator of a
research network. Those that returned comments are in
bold:
 Developmental anomalies: Pr. Koenraad Devriendt
(Belgium), Pr. Albert E. Chudley (Canada), Pr. Jane
Evans (Canada), Pr. Rachel Laframboise (Canada),
Dr. Marie Béland (Canada), Dr. Nicolas Gilbert
(Canada), Pr. Alain Verloes (France), Dr. Martine
Le Merrer (France), Dr. Agnès Bloch-Zupan
(France), Pr. Damien Bonnet (France), Dr. Lucile
Houyel (France) Pr. Raoul C. Hennekam
(Netherlands), Dr. Krystyna Chrzanowska (Poland),
Pr. Malgorzata Krajewska-Walasek (Poland), Dr.
Cristina Rusu (Romania), Pr. Petr Novikov (Russia),
Dr. Adeeb Al-Omrani (Saudi Arabia), Pr. Miguel del
Campo Casanelles (Spain), Dr. Sixto García-Miñaúr
(Spain), Pr. Albert Schinzel (Switzerland), Dr. Aída
Falcón (Venezuela), Dr. Rodney Franklin (United
Kingdom), Dr. Diana Wellesley (United Kingdom),
Dr. Michele Lloyd-Puryear (United States), Dr. John
Moeschler (United States), Pr. Robert H. Anderson
(United Kingdom), Pr. Dian Donnai & Mr. Han
Brunner (Dyscerne), Pr. Anthony Brookes
(Gen2Phen), Dr. Peter Robinson (Human Phenotype
Ontology), Dr. Helen V. Firth (Decipher), Dr. Ester
Garne (Eurocat), Pr. Ada Hamosh (Online
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Leeuw (European Cytogeneticists Association
Register of Unbalanced Chromosome Aberrations).
 Endocrinology: Pr. Sabina Zaharieva (Bulgaria), Pr.
Nikolai Botushanov (Bulgaria), Dr. Celia Rodd
(Canada), Dr. David Stephure (Canada), Dr. Marta
Šnajderová (Czech Republic), Dr. Vallo Tillmann
(Estonia), Dr. Kirsti Näntö-Salonen (Finland), Pr.
Philippe Chanson (France), Pr. Maïthé Tauber
(France), Dr. Felix Beuschlein (Germany), Dr.
Catherine Dacou-Voutetakis (Greece), Dr. Evangel-
ine Vasilatou (Greece), Dr. Marco Cappa (Italy), Pr.
Vincenzo Trischitta (Italy), Pr. Sebastiano Filetti
(Italy), Pr. Jolanta Sykut-Cegielska (Poland), Dr.
Eusebiu Zbranca (Romania), Dr. Anatoly Tiulpakov
(Russia), Pr. Susana Webb Youdale (Spain), Pr.
Angel Carrascosa (Spain), Dr. Rüveyde Bundak
(Turkey), Pr. Julian Davis (United Kingdom), Pr.
Gary Butler (United Kingdom).
 Gastroenterology, Nephrology, Diabetes: Dr. Griffin
Rogers (National Institute of Diabetes, Digestive and
Kidney Diseases, United States).
 Haematology: Dr. Dieter Lutz (Austria), Dr. Henrik
Birgens (Denmark), Dr. Vessela Goranova (Bulgaria),
Pr. Frédéric Galacteros (France), Pr. Hubert
Schrezenmeier (Germany), Dr. Panayiotis Tsaftaridis
(Greece), Dr. Paquita Nurden (France), Pr. Robin
Foà (Italy), Dr. Ecaterina Hanganu (Romania), Dr.
Michel Duchosal (Switzerland), Pr. Teoman Soysal
(Turkey), M.D. Inderjeet Dokal (United Kingdom),
Dr. Michael Leaker (Canada), Pr. Andrew Spencer
(Australia) Pr. Joan Lluís Vives Corrons (ENERCA),
Pr. Flora Peyvandi (Rare Blood Diseases Database),
Dr. Donna DiMichele (National Heart, Lung and
Blood Institute, United States).
 Immunology: Pr. Mariana Murdjeva (Bulgaria), Dr.
Reza Alizadehfar (Canada), Dr. Christine McCusker
(Canada), Dr. Nada Jabado (Canada), Dr. Raivo Uibo
(Estonia), Pr. Alain Fischer (France), Pr. Hans-
Hartmut Peter (Germany), Pr. C. G. M. Kallenberg
(Netherlands), Pr. Ewa Bernatowska (Poland), Dr.
Carlos Vasconcelos (Portugal), Dr. Eugen Carasevici
(Romania), Dr. Rahim Chaitov (Russia), Dr. Miguel
Lopez Botet (Spain), Dr. Cecilia Muñoz Calleja
(Spain), Dr. Nuria Matamoros Florí (Spain), Pr.
Günnur Deniz (Turkey), Pr. Luigi Daniele
Notarangelo (United States), Dr. Mort Cowan
(United States), Dr. Linda M. Griffith (United
States), Dr. Donna DiMichele (United States), Dr.
Henry Chang (United States), Pr. Mauno Vihinen
(Information Network for Immunodeficiencies), Pr.
Stephan H. E. Kaufmann (European Federation of
Immunological Societies), Pr. Amos Etzioni
(European Society for Immunodeficiencies), DavidWatters & Johan Prévot (International Patient
Organisation for Primary Immunodeficiencies), Pr.
Helen Chapel & Pr. Mimi Tang (International
Union of Immunological Societies).
 Inborn Errors of Metabolism: Dr. Wolfgang Sperl
(Austria), Pr. George van den Berghe (Belgium), Pr.
François Eyskens (Belgium), Dr. Jiří Zeman (Czech
Republic), Pr. Pascale de Lonlay (France), Pr.
Jean-Marie Saudubray (France), Pr. Udo Wendel
(Germany), Dr. Carlo Dionisi-Vici (Italy), Pr. Jan
Smeitink (Netherlands), Pr. Paula Grigorescu-Sido
(Romania), Dr. Ekaterina Zakharova (Russia), Dr.
Teresa Pàmpols Ros (Spain), Dr. Ali Dursun
(Turkey), Dr. Eduardo Wraith (United Kingdom),
Pr. James V. Leonard (United Kingdom), Dr. Sara
Copeland (United States), Dr. Susan Winter (United
States), Dr. Neil Buist (United States), : Dr. Mick
Henderson & Dr. James Bonham (ERNDIM), Dr.
Bryan Winchester (ESGLD), Mr. H. Stroomer
(Eumitocombat), Pr. Gert Matthijs (Euroglycanet),
Pr. Manuel Palacín Prieto (EUGINDAT), Pr.
Jean-Charles Deybach & Dr. Aasne Karine Aarsand
(European Porphyria Network), Pr. Paula Saftig
(HUE-MAN), Mrs. Rosy Engelen (Mitocircle), Pr.
Guy Besley (Society for the study of inborn errors of
metabolism), Dr. John Walter (British Inherited
Metabolic Diseases Group), Dr. Robert Naviaux
(United Mitochondrial Diseases Foundation).
 Neurology: Pr. Franz Aichner (Austria), Dr. Pavel
Balabanov (Bulgaria), Pr. Veneta Bojinova (Bulgaria),
Pr. Paraskeva Stamenova (Bulgaria), Dr. Michael
Shevell (Canada), Dr. Myriam Srour (Canada), Dr.
Karen Barlow (Canada), Pr. Tat’ána Maříková
(Czech Republic), Dr. John Vissing (Denmark), Dr.
Anneli Kolk (Estonia), Dr. Valentin Sander (Estonia),
Dr. Sulev Haldre (Estonia), Dr. Katrin Gross-Paju
(Estonia), Dr. Tiina Talvik (Estonia), Dr. Aki
Hietaharju (Finland), Pr. Juha E. Jääskeläinen
(Finland), Dr. Tiina Tyni (Finland), Pr. Philippe
Coubes (France), Pr. Olivier Dulac (France), Pr.
Bruno Eymard (France), Pr. Bertrand Fontaine
(France), Dr. Thomas Klockgether (Germany), Pr.
Thomas Voit (Germany), Dr. Sotiria Mastroyianni
(Greece), Dr. Sámual Komoly (Hungary), Dr.
Richard Petty (Ireland & United Kingdom), Dr.
Enrico Bertini (Italy), Dr. Luciano Merlini (Italy), Pr.
Francesco Muntoni (Italy), Dr. Enza Maria Valente
(Italy), Pr. Valmantas Budrys (Lithuania), Pr. Milda
Endziniene (Lithuania), Pr. Marianne De Wisser
(Netherlands), Pr. Felicia Stefanache (Romania), Pr.
Sergei Illarioshkin (Russia), Pr. Jaime Campos-
Castello (Spain), Dr. Hand Jung (Switzerland), Pr.
Piraye Serdaroglu (Turkey), Pr. Volker Straub & Pr.
Kate Bushby (TREAT-NMD), Dr. Solomon Moshe
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Wilson (Encephalitis Society), Pr. José Ferro
(European Neurological Society), Dr. Robin Grant
(European Association of Neurooncology), Pr.
Robert Ouvrier (International Child Neurology
Association), Dr. Alexandra Dürr (Spatax), Pr.
Alastair Compston (Association of British
Neurologists), Dr. Petra Kauffman (National
Institute of Neurological Disorders and Stroke,
United States).
 Nutritional diseases: Dr. Jeff Critch (Canada), Dr.
Stephanie Atkinson (Canada), Dr. Veronique Anne
Pelletier (Canada), Pr. Victor Tutelian (Russia).
 Respiratory diseases: Dr. Panayiotis Yiallouros
(Cyprus), Dr. Tacjana Pressler (Denmark), Dr. Maire
Vasar (Estonia), Dr. Rain Jõgi (Estonia), Dr. Katriina
Kahlos (Finland), Pr. Jean-François Cordier
(France), Pr. Joachim Müller-Quernheim (Germany),
Pr. Renato Cutrera (Italy), Pr. Edvardas Danila
(Lithuania), Pr. C. K. van der Ent (Netherlands), Pr.
João Carlos Winck (Portugal), Dr. Antonio Román
Broto (Spain), Dr. Julio Ancochea Bermúdez (Spain),
Dr. Juan José Morell Bernabé (Spain), Dr. Eeva
Piitulainen (Sweden), Dr. Romain Lazor
(Switzerland), Dr. Jeffrey Kaufman (United States),
Dr. Michael Schechter (United States), Dr. Edwin K.
Silverman (United States), Dr. Ivy Dunbar (United
States), Pr. Annick Clément (Reference centre for
rare respiratory diseases, Hôpital d’enfants Armand
Trousseau), Pr. Wim Wuyts (Interstitial lung disease
program - Leuven, Belgium), Dr. Colin Wallis (Brit-
ish Paediatric Respiratory Society), Dr. Stephen Con-
ellan (British Thoracic Society)
 Infectiology and Allergology: Dr. Anthony Fauci
(National institute of Allergy and Infectious
Diseases, United States)
 Oncology: Dr. Gemma Gatta (Rarecare).
 Paediatrics: Dr. Alan Guttmacher (National
Institute of Child Health and Human Development,
United States)
 Rheumatology and Dermatology: Dr. Stephen Katz
(National Institute of Arthritis, Musculoskeletal and
Skin Diseases, United States)Special thanks
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